University of Illinois at Chicago, Chicago, IL 60608, United States.
J Affect Disord. 2011 Jan;128(1-2):112-9. doi: 10.1016/j.jad.2010.06.013. Epub 2010 Sep 21.
The development of valid parent-report measures of symptom change in pediatric bipolar disorder (PBD) is imperative to evaluate the effectiveness of different treatment approaches; yet, few studies have tested the sensitivity of symptom measures. The current study evaluated the sensitivity of the Child Mania Rating Scale (CMRS-P) to detect symptom change over time in a treatment study for PBD.
Data on symptom change were drawn from a prospective six-week, double-blind, placebo-controlled, randomized outpatient medication treatment trial of risperidone versus divalproex. The sample included 66 children with Bipolar type I disorder. Measures were administered every week for six weeks of treatment.
The CMRS-P demonstrated statistically (p ≤ .05) and clinically significant change in symptom report from pre to post-test. Growth curve modeling indicated that the CMRS-P demonstrated overall similarity to the YMRS in the magnitude and trajectory of change over time. Finally, results indicate that the CMRS-P is able to detect response rates with moderate levels of agreement with other measures.
Limitations of this study include a relatively small sample size and uncertain generalizability beyond treatment trials.
The CMRS-P is short, easy to administer, and represents parent's report of symptoms, all strengths which make it a compelling treatment outcome tool. This preliminary evidence of its validity as a treatment outcome measure makes it applicable in other research settings and suggests its potential use in clinical settings.
开发有效的父母报告的儿童双相情感障碍（PBD）症状变化的措施是至关重要的，以评估不同治疗方法的有效性；然而，很少有研究测试症状测量的敏感性。本研究评估了儿童躁狂症评定量表（CMRS-P）在评估双相情感障碍治疗研究中随时间变化的敏感性。
症状变化的数据来自一项为期六周、双盲、安慰剂对照、随机门诊药物治疗试验，研究利培酮与丙戊酸钠治疗双相 I 型障碍。样本包括 66 名患有双相情感障碍 I 型障碍的儿童。在治疗的六周内每周进行一次评估。
CMRS-P 从预测试到后测试显示出统计学上（p ≤.05）和临床上显著的症状报告变化。增长曲线模型表明，CMRS-P 在随时间变化的幅度和轨迹上与 YMRS 总体相似。最后，结果表明，CMRS-P 能够以中等程度的一致性检测出与其他测量方法的反应率。
本研究的局限性包括样本量相对较小，以及治疗试验之外的不确定性。
CMRS-P 是简短的，易于管理，并且代表了父母对症状的报告，所有这些优势使其成为一种有吸引力的治疗结果工具。作为治疗结果测量的初步有效性证据使其适用于其他研究环境，并表明其在临床环境中的潜在用途。
